RxDoctor Payments Data

Shawna Steffes

Psychiatric/Mental Health · Peoria, AZNPI 1821614520

Payments from drug & device makers

$1,142in general payments, 2019–2025

Across 25 payments — averaging $45.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$519
  • Acadia Pharmaceuticals Inc$348
  • Alpha Cognition USA, Inc.$144
  • Teva Pharmaceuticals USA, Inc.$117
  • Avanir Pharmaceuticals, Inc.$14

What the payments were for

  • Food & beverage$1,03891%
  • Education$1049%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,142 in reported general payments places this provider in the 70th percentile of 1,230 psychiatric/mental health providers in Arizona.

See all psychiatric/mental health providers in Arizona

Medicare billing

Part B allowed, 2024
$119,356
Medicare patients
138
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate39$130,551
Divalproex Sodium279$15,150
Mirtazapine310$14,483
Sertraline Hcl363$8,174
Hydroxyzine Hcl264$8,172
Trazodone Hcl363$7,484
Aripiprazole70$6,777
Olanzapine136$4,960
Lorazepam286$4,910
Buspirone Hcl170$4,567
Oxcarbazepine35$4,010
Quetiapine Fumarate102$3,805
Risperidone135$3,390
Duloxetine Hcl57$2,965
Clonazepam84$1,398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$519$130,55139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,230 psychiatric/mental health providers in Arizona.

Other psychiatric/mental health in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →